Crescent (CBIO) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental analysis yields a 5.1/10 rating. Strengths include high cash‑to‑market (Cash‑MV), strong inventory turnover, solid PB‑ROE and robust YoY revenue growth. Weaknesses are negative asset‑to‑market, low revenue‑to‑market and poor gross margin, dragging the overall score.

Analysis Checks(6/10)

Revenue-MV

Value-2.35

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value2.12

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value-1.32

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value9.37

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight16.52%

1M Return5.94%

Is CBIO undervalued or overvalued?

CBIO scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -160.75% ROE, 0.00% net margin, -2.71 P/E ratio, 2.06 P/B ratio, and 44.97% earnings growth, these metrics solidify its Netural investment rating.